Gelsolin amyloidosis: genetics, biochemistry, pathology and possible strategies for therapeutic intervention

References

• Ardalan MR, Shoja MM, Kiuru-Enari S. 2007. Amyloidosis-related nephrotic syndrome due to a G654A gelsolin mutation: the first report from the Middle East. Nephrol Dial Transplant 22:272–275.
   PubMed Web of Science ®Google Scholar
• Arumugam TV, Cheng YL, Choi Y, Choi YH, Yang S, Yun YK, Park JS, Yang DK, Thundyil J, Gelderblom M, Karamyan VT, Tang SC, Chan SL, Magnus T, Sobey CG, Jo DG. 2011. Evidence that γ-secretase-mediated Notch signaling induces neuronal cell death via the nuclear factor-κB-Bcl-2-interacting mediator of cell death pathway in ischemic stroke. Mol Pharmacol 80:23–31.
   PubMed Web of Science ®Google Scholar
• Ashish Paine MS, Perryman PB, Yang L, Yin HL, Krueger JK. 2007. Global structure changes associated with Ca2+ activation of full-length human plasma gelsolin. J Biol Chem 282:25884–25892.
   PubMed Web of Science ®Google Scholar
• Balch WE, Morimoto RI, Dillin A, Kelly JW. 2008. Adapting proteostasis for disease intervention. Science 319:916–919.
   PubMed Web of Science ®Google Scholar
• Baures PW, Peterson SA, Kelly JW. 1998. Discovering transthyretin amyloid fibril inhibitors by limited screening. Bioorg Med Chem 6:1389–1401.
   PubMed Web of Science ®Google Scholar
• Baures PW, Oza VB, Peterson SA, Kelly JW. 1999. Synthesis and evaluation of inhibitors of transthyretin amyloid formation based on the non-steroidal anti-inflammatory drug, flufenamic acid. Bioorg Med Chem 7:1339–1347.
   PubMed Web of Science ®Google Scholar
• Bieschke J, Zhang Q, Bosco DA, Lerner RA, Powers ET, Wentworth P Jr, Kelly JW. 2006. Small molecule oxidation products trigger disease-associated protein misfolding. Acc Chem Res 39:611–619.
   PubMed Web of Science ®Google Scholar
• Bieschke J, Zhang Q, Powers ET, Lerner RA, Kelly JW. 2005. Oxidative metabolites accelerate Alzheimer’s amyloidogenesis by a two-step mechanism, eliminating the requirement for nucleation. Biochemistry 44:4977–4983.
   PubMed Web of Science ®Google Scholar
• Blake CC, Serpell LC, Sunde M, Sandgren O, Lundgren E. 1996. A molecular model of the amyloid fibril. Ciba Found Symp 199:6–15; discussion 15.
   PubMedGoogle Scholar
• Booth DR, Sunde M, Bellotti V, Robinson CV, Hutchinson WL, Fraser PE, Hawkins PN, Dobson CM, Radford SE, Blake CC, Pepys MB. 1997. Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature 385:787–793.
   PubMed Web of Science ®Google Scholar
• Bosco DA, Fowler DM, Zhang Q, Nieva J, Powers ET, Wentworth P Jr, Lerner RA, Kelly JW. 2006. Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate α-synuclein fibrilization. Nat Chem Biol 2:249–253.
   PubMed Web of Science ®Google Scholar
• Bourgault S, Solomon JP, Reixach N, Kelly JW. 2011. Sulfated glycosaminoglycans accelerate transthyretin amyloidogenesis by quaternary structural conversion. Biochemistry 50:1001–1015.
   PubMed Web of Science ®Google Scholar
• Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo J, Taddei N, Ramponi G, Dobson CM, Stefani M. 2002. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416:507–511.
   PubMed Web of Science ®Google Scholar
• Bucki R, Byfield FJ, Kulakowska A, McCormick ME, Drozdowski W, Namiot Z, Hartung T, Janmey PA. 2008a. Extracellular gelsolin binds lipoteichoic acid and modulates cellular response to proinflammatory bacterial wall components. J Immunol 181:4936–4944.
   PubMedGoogle Scholar
• Bucki R, Kulakowska A, Byfield FJ, Zendzian-Piotrowska M, Baranowski M, Marzec M, Winer JP, Ciccarelli NJ, Górski J, Drozdowski W, Bittman R, Janmey PA. 2010. Plasma gelsolin modulates cellular response to sphingosine 1-phosphate. Am J Physiol, Cell Physiol 299:C1516–C1523.
   Google Scholar
• Bucki R, Levental I, Kulakowska A, Janmey PA. 2008b. Plasma gelsolin: function, prognostic value, and potential therapeutic use. Curr Protein Pept Sci 9:541–551.
   PubMed Web of Science ®Google Scholar
• Burtnick LD, Koepf EK, Grimes J, Jones EY, Stuart DI, McLaughlin PJ, Robinson RC. 1997. The crystal structure of plasma gelsolin: implications for actin severing, capping, and nucleation. Cell 90:661–670.
   PubMed Web of Science ®Google Scholar
• Carrwik C, Stenevi U. 2009. Lattice corneal dystrophy, gelsolin type (Meretoja’s syndrome). Acta Ophthalmol 87:813–819.
   PubMed Web of Science ®Google Scholar
• Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan M, Waucquier N, Defebvre L, Amouyel P, Farrer M, Destée A. 2004. α-synuclein locus duplication as a cause of familial Parkinson’s disease. Lancet 364:1167–1169.
   PubMed Web of Science ®Google Scholar
• Chastan N, Baert-Desurmont S, Saugier-Veber P, Dérumeaux G, Cabot A, Frébourg T, Hannequin D. 2006. Cardiac conduction alterations in a French family with amyloidosis of the Finnish type with the p.Asp187Tyr mutation in the GSN gene. Muscle Nerve 33:113–119.
   PubMed Web of Science ®Google Scholar
• Chauhan V, Ji L, Chauhan A. 2008. Anti-amyloidogenic, anti-oxidant and anti-apoptotic role of gelsolin in Alzheimer’s disease. Biogerontology 9:381–389.
   PubMed Web of Science ®Google Scholar
• Chauhan VP, Ray I, Chauhan A, Wisniewski HM. 1999. Binding of gelsolin, a secretory protein, to amyloid β-protein. Biochem Biophys Res Commun 258:241–246.
   PubMed Web of Science ®Google Scholar
• Chen CD, Huff ME, Matteson J, Page L, Phillips R, Kelly JW, Balch WE. 2001. Furin initiates gelsolin familial amyloidosis in the Golgi through a defect in Ca(2+) stabilization. EMBO J 20:6277–6287.
   PubMed Web of Science ®Google Scholar
• Chiti F, Stefani M, Taddei N, Ramponi G, Dobson CM. 2003. Rationalization of the effects of mutations on peptide and protein aggregation rates. Nature 424:805–808.
   PubMed Web of Science ®Google Scholar
• Choe H, Burtnick LD, Mejillano M, Yin HL, Robinson RC, Choe S. 2002. The calcium activation of gelsolin: insights from the 3A structure of the G4-G6/actin complex. J Mol Biol 324:691–702.
   PubMedGoogle Scholar
• Choo DW, Schneider JP, Graciani NR, Kelly JW. 1996. Nucleated antiparallel Œ≤-sheet that folds and undergoes self-assembly: a template promoted folding strategy toward controlled molecular architectures. Macromolecules 29:355–366.
   Google Scholar
• Coelho T, Maia L, Da Silva AM, Cruz MW, Plante-Bordeneuve V, Lozeron P, Suhr OB, Campistol J, Conceicao I, Schmidt H, Trigo P, Packman J, Grogan DR. 2011. A comprehensive evaluation of the disease-modifying effects of tafamidis in patients with transthyretin type familial amyloid polyneuropathy. Neurology 76:A111–A111.
   Google Scholar
• Cohen E, Paulsson JF, Blinder P, Burstyn-Cohen T, Du D, Estepa G, Adame A, Pham HM, Holzenberger M, Kelly JW, Masliah E, Dillin A. 2009. Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell 139:1157–1169.
   PubMed Web of Science ®Google Scholar
• Cohen FE, Kelly JW. 2003. Therapeutic approaches to protein-misfolding diseases. Nature 426:905–909.
   PubMed Web of Science ®Google Scholar
• Conceição I, Sales-Luis ML, De Carvalho M, Evangelista T, Fernandes R, Paunio T, Kangas H, Coutinho P, Neves C, Saraiva MJ. 2003. Gelsolin-related familial amyloidosis, Finnish type, in a Portuguese family: clinical and neurophysiological studies. Muscle Nerve 28:715–721.
   PubMed Web of Science ®Google Scholar
• Contégal F, Bidot S, Thauvin C, Lévèque L, Soichot P, Gras P, Moreau T, Giroud M. 2006. Finnish amyloid polyneuropathy in a French patient. Rev Neurol (Paris) 162:997–1001.
   PubMed Web of Science ®Google Scholar
• De La Chapelle A, Tolvanen R, Boysen G, Santavy J, Bleekerwagemakers L, Maury CPJ, Kere J. 1992. Gelsolin-derived familial amyloidosis caused by asparagine or tyrosine substitution for aspartic acid at residue 187. Nat Genet 2:157–160.
   PubMed Web of Science ®Google Scholar
• Dobson CM. 2003. Protein folding and misfolding. Nature 426:884–890.
   PubMed Web of Science ®Google Scholar
• Engel WK, Askanas V. 2006. Inclusion-body myositis: clinical, diagnostic, and pathologic aspects. Neurology 66:S20–S29.
   Web of Science ®Google Scholar
• Falzone TL, Gunawardena S, McCleary D, Reis GF, Goldstein LS. 2010. Kinesin-1 transport reductions enhance human tau hyperphosphorylation, aggregation and neurodegeneration in animal models of tauopathies. Hum Mol Genet 19:4399–4408.
   PubMed Web of Science ®Google Scholar
• Fändrich M, Fletcher MA, Dobson CM. 2001. Amyloid fibrils from muscle myoglobin. Nature 410:165–166.
   PubMed Web of Science ®Google Scholar
• Felix EPV, Jung LS, Carvalho GS, Oliveira ASB. 2008. Corneal lattic dystrophy type II: Familial amyloid neuropathy type IV (gelsolin amyloidosis). Einstein 6:505–506.
   Google Scholar
• Fernandez-Escamilla AM, Rousseau F, Schymkowitz J, Serrano L. 2004. Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins. Nat Biotechnol 22:1302–1306.
   PubMed Web of Science ®Google Scholar
• Ferrone F. 1999. Analysis of protein aggregation kinetics. Amyloid, Prions, and Other Protein Aggregates San Diego: Academic Press Inc.
   Google Scholar
• Gandhi NS, Mancera RL. 2008. The structure of glycosaminoglycans and their interactions with proteins. Chem Biol Drug Des 72:455–482.
   PubMed Web of Science ®Google Scholar
• Green NS, Palaninathan SK, Sacchettini JC, Kelly JW. 2003. Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization. J Am Chem Soc 125:13404–13414.
   PubMed Web of Science ®Google Scholar
• Güntert A, Campbell J, Saleem M, O’Brien DP, Thompson AJ, Byers HL, Ward MA, Lovestone S. 2010. Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer’s disease. J Alzheimers Dis 21:585–596.
   PubMedGoogle Scholar
• Haltia M, Prelli F, Ghiso J, Kiuru S, Somer H, Palo J, Frangione B. 1990. Amyloid protein in familial amyloidosis (Finnish type) is homologous to gelsolin, an actin-binding protein. Biochem Biophys Res Commun 167:927–932.
   PubMed Web of Science ®Google Scholar
• Hammarström P, Sekijima Y, White JT, Wiseman RL, Lim A, Costello CE, Altland K, Garzuly F, Budka H, Kelly JW. 2003a. D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis? Biochemistry 42:6656–6663.
   PubMed Web of Science ®Google Scholar
• Hammarström P, Jiang X, Hurshman AR, Powers ET, Kelly JW. 2002. Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity. Proc Natl Acad Sci USA 99 Suppl 4:16427–16432.
   PubMedGoogle Scholar
• Hammarström P, Schneider F, Kelly JW. 2001. Trans-suppression of misfolding in an amyloid disease. Science 293:2459–2462.
   PubMed Web of Science ®Google Scholar
• Hammarström P, Wiseman RL, Powers ET, Kelly JW. 2003b. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 299:713–716.
   PubMed Web of Science ®Google Scholar
• Hartl FU, Bracher A, Hayer-Hartl M. 2011. Molecular chaperones in protein folding and proteostasis. Nature 475:324–332.
   PubMed Web of Science ®Google Scholar
• Her LS, Goldstein LS. 2008. Enhanced sensitivity of striatal neurons to axonal transport defects induced by mutant huntingtin. J Neurosci 28:13662–13672.
   PubMedGoogle Scholar
• Hirko AC, Meyer EM, King MA, Hughes JA. 2007. Peripheral transgene expression of plasma gelsolin reduces amyloid in transgenic mouse models of Alzheimer’s disease. Mol Ther 15:1623–1629.
   PubMedGoogle Scholar
• Huerva V, Velasco A, Sánchez MC, Mateo AJ, Matías-Guiu X. 2007. Lattice corneal dystrophy type II: clinical, pathologic, and molecular study in a Spanish family. Eur J Ophthalmol 17:424–429.
   PubMedGoogle Scholar
• Huff ME, Balch WE, Kelly JW. 2003a. Pathological and functional amyloid formation orchestrated by the secretory pathway. Curr Opin Struct Biol 13:674–682.
   PubMed Web of Science ®Google Scholar
• Huff ME, Page LJ, Balch WE, Kelly JW. 2003b. Gelsolin domain 2 Ca2+ affinity determines susceptibility to furin proteolysis and familial amyloidosis of Finnish type. J Mol Biol 334:119–127.
   PubMed Web of Science ®Google Scholar
• Hurshman Babbes AR, Powers ET, Kelly JW. 2008. Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis. Biochemistry 47:6969–6984.
   PubMed Web of Science ®Google Scholar
• Ibáñez P, Bonnet AM, Débarges B, Lohmann E, Tison F, Pollak P, Agid Y, Dürr A, Brice A. 2004. Causal relation between α-synuclein gene duplication and familial Parkinson’s disease. Lancet 364:1169–1171.
   PubMedGoogle Scholar
• Ikeda M, Mizushima K, Fujita Y, Watanabe M, Sasaki A, Makioka K, Enoki M, Nakamura M, Otani T, Takatama M, Okamoto K. 2007. Familial amyloid polyneuropathy (Finnish type) in a Japanese family: clinical features and immunocytochemical studies. J Neurol Sci 252:4–8.
   PubMed Web of Science ®Google Scholar
• Imbimbo BP, Giardina GA. 2011. γ-secretase inhibitors and modulators for the treatment of Alzheimer’s disease: disappointments and hopes. Curr Top Med Chem 11:1555–1570.
   PubMed Web of Science ®Google Scholar
• Ji L, Chauhan A, Chauhan V. 2008. Cytoplasmic gelsolin in pheochromocytoma-12 cells forms a complex with amyloid beta-protein. Neuroreport 19:463–466.
   PubMedGoogle Scholar
• Jiang X, Buxbaum JN, Kelly JW. 2001. The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis. Proc Natl Acad Sci USA 98:14943–14948.
   PubMed Web of Science ®Google Scholar
• Jiao GS, Cregar L, Wang J, Millis SZ, Tang C, O’Malley S, Johnson AT, Sareth S, Larson J, Thomas G. 2006. Synthetic small molecule furin inhibitors derived from 2,5-dideoxystreptamine. Proc Natl Acad Sci USA 103:19707–19712.
   PubMed Web of Science ®Google Scholar
• Johnson SM, Wiseman RL, Sekijima Y, Green NS, Adamski-Werner SL, Kelly JW. 2005. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Acc Chem Res 38:911–921.
   PubMed Web of Science ®Google Scholar
• Kangas H, Paunio T, Kalkkinen N, Jalanko A, Peltonen L. 1996. In vitro expression analysis shows that the secretory form of gelsolin is the sole source of amyloid in gelsolin-related amyloidosis. Hum Mol Genet 5:1237–1243.
   PubMed Web of Science ®Google Scholar
• Kangas H, Seidah NG, Paunio T. 2002. Role of proprotein convertases in the pathogenic processing of the amyloidosis-associated form of secretory gelsolin. Amyloid 9:83–87.
   PubMed Web of Science ®Google Scholar
• Kazmirski SL, Isaacson RL, An C, Buckle A, Johnson CM, Daggett V, Fersht AR. 2002. Loss of a metal-binding site in gelsolin leads to familial amyloidosis-Finnish type. Nat Struct Biol 9:112–116.
   PubMedGoogle Scholar
• Kelly JW. 1996. Alternative conformations of amyloidogenic proteins govern their behavior. Curr Opin Struct Biol 6:11–17.
   PubMed Web of Science ®Google Scholar
• Kelly JW. 1998. The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr Opin Struct Biol 8:101–106.
   PubMed Web of Science ®Google Scholar
• Khaitlina S, Hinssen H. 2002. Ca-dependent binding of actin to gelsolin. FEBS Lett 521:14–18.
   PubMedGoogle Scholar
• Kiuru-Enari S, Keski-Oja J, Haltia M. 2005. Cutis laxa in hereditary gelsolin amyloidosis. Br J Dermatol 152:250–257.
   PubMed Web of Science ®Google Scholar
• Kiuru-Enari S, Somer H, Seppäläinen AM, Notkola IL, Haltia M. 2002. Neuromuscular pathology in hereditary gelsolin amyloidosis. J Neuropathol Exp Neurol 61:565–571.
   PubMed Web of Science ®Google Scholar
• Kiuru S. 1998. Gelsolin-related familial amyloidosis, Finnish type (FAF), and its variants found worldwide. Amyloid 5:55–66.
   PubMed Web of Science ®Google Scholar
• Kiuru S, Matikainen E, Kupari M, Haltia M, Palo J. 1994. Autonomic nervous system and cardiac involvement in familial amyloidosis, Finnish type (FAF). J Neurol Sci 126:40–48.
   PubMed Web of Science ®Google Scholar
• Kivelä T, Tarkkanen A, Frangione B, Ghiso J, Haltia M. 1994. Ocular amyloid deposition in familial amyloidosis, Finnish: an analysis of native and variant gelsolin in Meretoja’s syndrome. Invest Ophthalmol Vis Sci 35:3759–3769.
   PubMed Web of Science ®Google Scholar
• Kolstoe SE, Mangione PP, Bellotti V, Taylor GW, Tennent GA, Deroo S, Morrison AJ, Cobb AJ, Coyne A, McCammon MG, Warner TD, Mitchell J, Gill R, Smith MD, Ley SV, Robinson CV, Wood SP, Pepys MB. 2010. Trapping of palindromic ligands within native transthyretin prevents amyloid formation. Proc Natl Acad Sci USA 107:20483–20488.
   PubMed Web of Science ®Google Scholar
• Kwiatkowski DJ, Mehl R, Izumo S, Nadal-Ginard B, Yin HL. 1988. Muscle is the major source of plasma gelsolin. J Biol Chem 263:8239–8243.
   PubMedGoogle Scholar
• Kwiatkowski DJ, Stossel TP, Orkin SH, Mole JE, Colten HR, Yin HL. 1986. Plasma and cytoplasmic gelsolins are encoded by a single gene and contain a duplicated actin-binding domain. Nature 323:455–458.
   PubMed Web of Science ®Google Scholar
• Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL. 1998. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95:6448–6453.
   PubMed Web of Science ®Google Scholar
• Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT Jr. 2002. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418:291.
   PubMed Web of Science ®Google Scholar
• Lee J, Culyba EK, Powers ET, Kelly JW. 2011. Amyloid-β forms fibrils by nucleated conformational conversion of oligomers. Nat Chem Biol 7:602–609.
   PubMed Web of Science ®Google Scholar
• Lee PS, Waxman AB, Cotich KL, Chung SW, Perrella MA, Stossel TP. 2007. Plasma gelsolin is a marker and therapeutic agent in animal sepsis. Crit Care Med 35:849–855.
   PubMed Web of Science ®Google Scholar
• Liepina I, Czaplewski C, Janmey P, Liwo A. 2003. Molecular dynamics study of a gelsolin-derived peptide binding to a lipid bilayer containing phosphatidylinositol 4,5-bisphosphate. Biopolymers 71:49–70.
   PubMedGoogle Scholar
• Lomakin A, Teplow DB, Kirschner DA, Benedek GB. 1997. Kinetic theory of fibrillogenesis of amyloid β-protein. Proc Natl Acad Sci USA 94:7942–7947.
   PubMed Web of Science ®Google Scholar
• Lueck A, Yin HL, Kwiatkowski DJ, Allen PG. 2000. Calcium regulation of gelsolin and adseverin: a natural test of the helix latch hypothesis. Biochemistry 39:5274–5279.
   PubMedGoogle Scholar
• Lüttmann RJ, Teismann I, Husstedt IW, Ringelstein EB, Kuhlenbäumer G. 2010. Hereditary amyloidosis of the Finnish type in a German family: clinical and electrophysiological presentation. Muscle Nerve 41:679–684.
   PubMedGoogle Scholar
• Lührs T, Ritter C, Adrian M, Riek-Loher D, Bohrmann B, Döbeli H, Schubert D, Riek R. 2005. 3D structure of Alzheimer’s amyloid-β(1-42) fibrils. Proc Natl Acad Sci USA 102:17342–17347.
   PubMed Web of Science ®Google Scholar
• Mahalka AK, Maury CP, Kinnunen PK. 2011. 1-Palmitoyl-2-(9′-oxononanoyl)-sn-glycero-3-phosphocholine, an oxidized phospholipid, accelerates Finnish type familial gelsolin amyloidosis in vitro. Biochemistry 50:4877–4889.
   PubMed Web of Science ®Google Scholar
• Makioka K, Ikeda M, Ikeda Y, Nakasone A, Osawa T, Sasaki A, Otani T, Arai M, Okamoto K. 2010. Familial amyloid polyneuropathy (Finnish type) presenting multiple cranial nerve deficits with carpal tunnel syndrome and orthostatic hypotension. Neurol Res 32:472–475.
   PubMed Web of Science ®Google Scholar
• Maury CP. 1991. Gelsolin-related amyloidosis. Identification of the amyloid protein in Finnish hereditary amyloidosis as a fragment of variant gelsolin. J Clin Invest 87:1195–1199.
   PubMed Web of Science ®Google Scholar
• Maury CP. 1993. Homozygous familial amyloidosis, Finnish type: demonstration of glomerular gelsolin-derived amyloid and non-amyloid tubular gelsolin. Clin Nephrol 40:53–56.
   PubMed Web of Science ®Google Scholar
• Maury CP, Nurmiaho-Lassila EL, Rossi H. 1994. Amyloid fibril formation in gelsolin-derived amyloidosis. Definition of the amyloidogenic region and evidence of accelerated amyloid formation of mutant Asn-187 and Tyr-187 gelsolin peptides. Lab Invest 70:558–564.
   PubMed Web of Science ®Google Scholar
• Meretoja J. 1969. Familial systemic paramyloidosis with lattice dystrophy of the cornea, progressive cranial neuropathy, skin changes and various internal symptoms. A previously unrecognized heritable syndrome. Ann Clin Res 1:314–324.
   PubMedGoogle Scholar
• Meretoja J. 1973. Genetic aspects of familial amyloidosis with corneal lattice dystrophy and cranial neuropathy. Clin Genet 4:173–185.
   PubMed Web of Science ®Google Scholar
• Miller SR, Sekijima Y, Kelly JW. 2004. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest 84:545–552.
   PubMed Web of Science ®Google Scholar
• Nag S, Ma Q, Wang H, Chumnarnsilpa S, Lee WL, Larsson M, Kannan B, Hernandez-Valladares M, Burtnick LD, Robinson RC. 2009. Ca2+ binding by domain 2 plays a critical role in the activation and stabilization of gelsolin. Proc Natl Acad Sci USA 106:13713–13718.
   PubMedGoogle Scholar
• Nelson R, Sawaya MR, Balbirnie M, Madsen AØ, Riekel C, Grothe R, Eisenberg D. 2005. Structure of the cross-β spine of amyloid-like fibrils. Nature 435:773–778.
   PubMed Web of Science ®Google Scholar
• Olzscha H, Schermann SM, Woerner AC, Pinkert S, Hecht MH, Tartaglia GG, Vendruscolo M, Hayer-Hartl M, Hartl FU, Vabulas RM. 2011. Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions. Cell 144:67–78.
   PubMed Web of Science ®Google Scholar
• Ong DS, Mu TW, Palmer AE, Kelly JW. 2010. Endoplasmic reticulum Ca2+ increases enhance mutant glucocerebrosidase proteostasis. Nat Chem Biol 6:424–432.
   PubMedGoogle Scholar
• Oza VB, Smith C, Raman P, Koepf EK, Lashuel HA, Petrassi HM, Chiang KP, Powers ET, Sachettinni J, Kelly JW. 2002. Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors. J Med Chem 45:321–332.
   PubMed Web of Science ®Google Scholar
• Page LJ, Huff ME, Kelly JW, Balch WE. 2004. Ca2+ binding protects against gelsolin amyloidosis. Biochem Biophys Res Commun 322:1105–1110.
   PubMedGoogle Scholar
• Page LJ, Suk JY, Bazhenova L, Fleming SM, Wood M, Jiang Y, Guo LT, Mizisin AP, Kisilevsky R, Shelton GD, Balch WE, Kelly JW. 2009. Secretion of amyloidogenic gelsolin progressively compromises protein homeostasis leading to the intracellular aggregation of proteins. Proc Natl Acad Sci USA 106:11125–11130.
   PubMed Web of Science ®Google Scholar
• Page LJ, Suk JY, Huff ME, Lim HJ, Venable J, Yates J, Kelly JW, Balch WE. 2005. Metalloendoprotease cleavage triggers gelsolin amyloidogenesis. EMBO J 24:4124–4132.
   PubMed Web of Science ®Google Scholar
• Park SM, Hwang IK, Kim SY, Lee SJ, Park KS, Lee ST. 2006. Characterization of plasma gelsolin as a substrate for matrix metalloproteinases. Proteomics 6:1192–1199.
   PubMed Web of Science ®Google Scholar
• Paunio T, Kangas H, Kalkkinen N, Haltia M, Palo J, Peltonen L. 1994. Toward understanding the pathogenic mechanisms in gelsolin-related amyloidosis:in vitro expression reveals an abnormal gelsolin fragment. Hum Mol Genet 3:2223–2229.
   PubMed Web of Science ®Google Scholar
• Pepys MB. 2006. Amyloidosis. Annu Rev Med 57:223–241.
   PubMed Web of Science ®Google Scholar
• Petkova AT, Ishii Y, Balbach JJ, Antzutkin ON, Leapman RD, Delaglio F, Tycko R. 2002. A structural model for Alzheimer’s β-amyloid fibrils based on experimental constraints from solid state NMR. Proc Natl Acad Sci USA 99:16742–16747.
   PubMed Web of Science ®Google Scholar
• Petrassi HM, Klabunde T, Sacchettini J, Kelly JW. 2000. Structure-based design of n-phenyl phenoxazine transthyretin amyloid fibril inhibitors. J Am Chem So 122:2178–2192.
   Web of Science ®Google Scholar
• Pihlamaa T, Rautio J, Kiuru-Enari S, Suominen S. 2011. Gelsolin amyloidosis as a cause of early aging and progressive bilateral facial paralysis. Plast Reconstr Surg 127:2342–2351.
   PubMed Web of Science ®Google Scholar
• Planté-Bordeneuve V, Said G. 2011. Familial amyloid polyneuropathy. Lancet Neurol 10:1086–1097.
   PubMed Web of Science ®Google Scholar
• Powers ET, Powers DL. 2008. Mechanisms of protein fibril formation: nucleated polymerization with competing off-pathway aggregation. Biophys J 94:379–391.
   PubMed Web of Science ®Google Scholar
• Ratnaswamy G, Huff ME, Su AI, Rion S, Kelly JW. 2001. Destabilization of Ca2+-free gelsolin may not be responsible for proteolysis in familial amyloidosis of Finnish type. Proc Natl Acad Sci USA 98:2334–2339.
   PubMed Web of Science ®Google Scholar
• Ratnaswamy G, Koepf E, Bekele H, Yin H, Kelly JW. 1999. The amyloidogenicity of gelsolin is controlled by proteolysis and pH. Chem Biol 6:293–304.
   PubMedGoogle Scholar
• Ray I, Chauhan A, Wegiel J, Chauhan VP. 2000. Gelsolin inhibits the fibrillization of amyloid β-protein, and also defibrillizes its preformed fibrils. Brain Res 853:344–351.
   PubMedGoogle Scholar
• Robinson RC, Mejillano M, Le VP, Burtnick LD, Yin HL, Choe S. 1999. Domain movement in gelsolin: a calcium-activated switch. Science 286:1939–1942.
   PubMedGoogle Scholar
• Rosenberg ME, Tervo TM, Gallar J, Acosta MC, Müller LJ, Moilanen JA, Tarkkanen AH, Vesaluoma MH. 2001. Corneal morphology and sensitivity in lattice dystrophy type II (familial amyloidosis, Finnish type). Invest Ophthalmol Vis Sci 42:634–641.
   PubMed Web of Science ®Google Scholar
• Roustan C, Ferjani I, Maciver SK, Fattoum A, Rebière B, Benyamin Y. 2007. Calcium-induced conformational changes in the amino-terminal half of gelsolin. FEBS Lett 581:681–686.
   PubMedGoogle Scholar
• Sabaté R, Estelrich J. 2005. Evidence of the existence of micelles in the fibrillogenesis of beta-amyloid peptide. J Phys Chem B 109:11027–11032.
   PubMedGoogle Scholar
• Sambamurti K, Greig NH, Utsuki T, Barnwell EL, Sharma E, Mazell C, Bhat NR, Kindy MS, Lahiri DK, Pappolla MA. 2011. Targets for AD treatment: conflicting messages from γ-secretase inhibitors. J Neurochem 117:359–374.
   PubMed Web of Science ®Google Scholar
• Sawaya MR, Sambashivan S, Nelson R, Ivanova MI, Sievers SA, Apostol MI, Thompson MJ, Balbirnie M, Wiltzius JJ, McFarlane HT, Madsen AØ, Riekel C, Eisenberg D. 2007. Atomic structures of amyloid cross-beta spines reveal varied steric zippers. Nature 447:453–457.
   PubMed Web of Science ®Google Scholar
• Schor NF. 2011. What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us. Ann Neurol 69:237–239.
   PubMed Web of Science ®Google Scholar
• Sekijima Y, Wiseman RL, Matteson J, Hammarström P, Miller SR, Sawkar AR, Balch WE, Kelly JW. 2005. The biological and chemical basis for tissue-selective amyloid disease. Cell 121:73–85.
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. 2003. Folding proteins in fatal ways. Nature 426:900–904.
   PubMed Web of Science ®Google Scholar
• Serio TR, Cashikar AG, Kowal AS, Sawicki GJ, Moslehi JJ, Serpell L, Arnsdorf MF, Lindquist SL. 2000. Nucleated conformational conversion and the replication of conformational information by a prion determinant. Science 289:1317–1321.
   PubMed Web of Science ®Google Scholar
• Shah SB, Nolan R, Davis E, Stokin GB, Niesman I, Canto I, Glabe C, Goldstein LS. 2009. Examination of potential mechanisms of amyloid-induced defects in neuronal transport. Neurobiol Dis 36:11–25.
   PubMedGoogle Scholar
• Shewmaker F, Kryndushkin D, Chen B, Tycko R, Wickner RB. 2009. Two prion variants of Sup35p have in-register parallel beta-sheet structures, independent of hydration. Biochemistry 48:5074–5082.
   PubMed Web of Science ®Google Scholar
• Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K. 2003. α-Synuclein locus triplication causes Parkinson’s disease. Science 302:841.
   PubMed Web of Science ®Google Scholar
• Snow AD, Willmer J, Kisilevsky R. 1987. Sulfated glycosaminoglycans: a common constituent of all amyloids Lab Invest 56:120–123.
   PubMed Web of Science ®Google Scholar
• Solomon JP, Bourgault S, Powers ET, Kelly JW. 2011. Heparin binds 8 kDa gelsolin cross-β-sheet oligomers and accelerates amyloidogenesis by hastening fibril extension. Biochemistry 50:2486–2498.
   PubMedGoogle Scholar
• Solomon JP, Yonemoto IT, Murray AN, Price JL, Powers ET, Balch WE, Kelly JW. 2009. The 8 and 5 kDa fragments of plasma gelsolin form amyloid fibrils by a nucleated polymerization mechanism, while the 68 kDa fragment is not amyloidogenic. Biochemistry 48:11370–11380.
   PubMed Web of Science ®Google Scholar
• Stewart HS, Parveen R, Ridgway AE, Bonshek R, Black GC. 2000. Late onset lattice corneal dystrophy with systemic familial amyloidosis, amyloidosis V, in an English family. Br J Ophthalmol 84:390–394.
   PubMed Web of Science ®Google Scholar
• Stokin GB, Goldstein LS. 2006. Axonal transport and Alzheimer’s disease. Annu Rev Biochem 75:607–627.
   PubMed Web of Science ®Google Scholar
• Suk JY, Zhang F, Balch WE, Linhardt RJ, Kelly JW. 2006. Heparin accelerates gelsolin amyloidogenesis. Biochemistry 45:2234–2242.
   PubMed Web of Science ®Google Scholar
• Sun HQ, Yamamoto M, Mejillano M, Yin HL. 1999. Gelsolin, a multifunctional actin regulatory protein. J Biol Chem 274:33179–33182.
   PubMed Web of Science ®Google Scholar
• Tanskanen M, Paetau A, Salonen O, Salmi T, Lamminen A, Lindsberg P, Somer H, Kiuru-Enari S. 2007. Severe ataxia with neuropathy in hereditary gelsolin amyloidosis: a case report. Amyloid 14:89–95.
   PubMed Web of Science ®Google Scholar
• Tanzi RE, Bertram L. 2005. Twenty years of the Alzheimer’s disease amyloid hypothesis: a genetic perspective. Cell 120:545–555.
   PubMed Web of Science ®Google Scholar
• Tycko R. 2003. Insights into the amyloid folding problem from solid-state NMR. Biochemistry 42:3151–3159.
   PubMed Web of Science ®Google Scholar
• Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. 2002. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416:535–539.
   PubMed Web of Science ®Google Scholar
• Walsh DM, Selkoe DJ. 2007. A β oligomers - a decade of discovery. J Neurochem 101:1172–1184.
   PubMed Web of Science ®Google Scholar
• Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B, Viola KL, Klein WL, Stine WB, Krafft GA, Trommer BL. 2002. Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res 924:133–140.
   PubMed Web of Science ®Google Scholar
• Wang H, Chumnarnsilpa S, Loonchanta A, Li Q, Kuan YM, Robine S, Larsson M, Mihalek I, Burtnick LD, Robinson RC. 2009. Helix straightening as an activation mechanism in the gelsolin superfamily of actin regulatory proteins. J Biol Chem 284:21265–21269.
   PubMedGoogle Scholar
• Wen D, Corina K, Chow EP, Miller S, Janmey PA, Pepinsky RB. 1996. The plasma and cytoplasmic forms of human gelsolin differ in disulfide structure. Biochemistry 35:9700–9709.
   PubMedGoogle Scholar
• Wiseman RL, Powers ET, Buxbaum JN, Kelly JW, Balch WE. 2007. An adaptable standard for protein export from the endoplasmic reticulum. Cell 131:809–821.
   PubMed Web of Science ®Google Scholar
• Witke W, Sharpe AH, Hartwig JH, Azuma T, Stossel TP, Kwiatkowski DJ. 1995. Hemostatic, inflammatory, and fibroblast responses are blunted in mice lacking gelsolin. Cell 81:41–51.
   PubMed Web of Science ®Google Scholar
• Yin HL, Kwiatkowski DJ, Mole JE, Cole FS. 1984. Structure and biosynthesis of cytoplasmic and secreted variants of gelsolin. J Biol Chem 259:5271–5276.
   PubMed Web of Science ®Google Scholar
• Yin HL, Stossel TP. 1979. Control of cytoplasmic actin gel-sol transformation by gelsolin, a calcium-dependent regulatory protein. Nature 281:583–586.
   PubMed Web of Science ®Google Scholar
• Yu Z, Sawkar AR, Whalen LJ, Wong CH, Kelly JW. 2007. Isofagomine- and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention. J Med Chem 50:94–100.
   PubMed Web of Science ®Google Scholar
• Zhou A, Webb G, Zhu X, Steiner DF. 1999. Proteolytic processing in the secretory pathway. J Biol Chem 274:20745–20748.
   PubMed Web of Science ®Google Scholar